M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Valproic Acid and Bevacizumab in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Valproic Acid
Drug: Bevacizumab

First Posted Date: 2007-09-18

Last Posted Date: 2015-01-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 71

Registration Number: NCT00530907

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

4-Dimensional CT Derived Ventilation Versus SPECT Aerosol Ventilation in Patients With Thoracic Malignancies

Phase 2

Completed

Conditions: Esophageal Cancer
Lung Cancer

Interventions: Procedure: 4D CT scans
Procedure: Lung Function Imaging

First Posted Date: 2007-09-18

Last Posted Date: 2018-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00531180

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Azacitidine
Drug: Valproic Acid
Drug: Carboplatin

First Posted Date: 2007-09-14

Last Posted Date: 2013-02-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT00529022

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Effect on Clip Markers After Vacuum-Assisted Biopsy by Postprocedure Mammogram

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Procedure: Breast Biopsy
Procedure: Post Procedure Mammogram

First Posted Date: 2007-09-14

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 61

Registration Number: NCT00529737

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Spectroscopy Versus Standard Care in Cervical Cancer Patients

Phase 3

Terminated

Conditions: Cervical Cancer

Interventions: Procedure: Colposcopy
Procedure: Fluorescence Spectroscopy
Procedure: LEEP Procedure

First Posted Date: 2007-09-14

Last Posted Date: 2016-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00529464

Locations: 🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦
British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada

Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes

Terminated

Conditions: Hypogonadism
Pain
Advanced Cancer

Interventions: Behavioral: Questionnaire
Other: Blood draws to assess gonadal function

First Posted Date: 2007-09-14

Last Posted Date: 2018-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00529230

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Mexican and African American Family Focus Groups on Puberty

Completed

Conditions: Healthy

Interventions: Behavioral: Focus Group

First Posted Date: 2007-09-12

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT00528762

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Lidocaine Supplement for Minimal Invasive Parathyroid Surgery

Phase 3

Withdrawn

Conditions: Parathyroid Disease

Interventions: Drug: Saline
Drug: Lidocaine

First Posted Date: 2007-09-12

Last Posted Date: 2012-12-07

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00528502

Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer

Phase 2

Terminated

Conditions: Head and Neck Cancer
Lung Cancer

Interventions: Drug: Celecoxib

First Posted Date: 2007-09-11

Last Posted Date: 2012-12-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00527982

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

Phase 1

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: Cisplatin
Drug: Docetaxel
Drug: Temodar

First Posted Date: 2007-09-11

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00527761

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy